Literature DB >> 23814982

[Atrial fibrillation in Germany--epidemiology, diagnosis, treatment and costs].

Karin Bramlage1, Martin Thoenes, Ulrich Tebbe, Peter Bramlage, Jürgen Wasem.   

Abstract

Atrial fibrillation is the most common cardiac arrhythmia. It is an independent risk factor for cardiovascular complications and stroke. The treatment options for atrial fibrillation have changed significantly in recent years by new drugs and ablative procedures. It is based on the principal strategies of anticoagulation, rhythm and rate control. Goal is to reduce symptoms and subsequent events. Although the costs of about 700 to pound 800 per patient per year are rather high, new treatment options might be associated with a reduction in event rates and an increase in quality adjusted life years (QALYs). The aim of this review is to give a practical overview of the epidemiology, diagnosis, treatment and costs to pharmacists who have a key role in the implementation of pharmacotherapy of atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23814982

Source DB:  PubMed          Journal:  Med Monatsschr Pharm        ISSN: 0342-9601


  2 in total

1.  Cost-effectiveness of a photopethysmographic procedure for screening for atrial fibrillation in 6 European countries.

Authors:  Steffen Wahler; Ralf Birkemeyer; Dimitrios Alexopoulos; Zbigniew Siudak; Alfred Müller; Johann-Matthias von der Schulenburg
Journal:  Health Econ Rev       Date:  2022-02-26

2.  A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany.

Authors:  Ralf Birkemeyer; Alfred Müller; Steffen Wahler; Johann-Matthias von der Schulenburg
Journal:  Health Econ Rev       Date:  2020-06-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.